July 4, 2023

Ip­ca Lab­o­ra­to­ries, an In­dia-based mak­er of ac­tive phar­ma­ceu­ti­cal in­gre­di­ents, was cit­ed for sev­er­al qual­i­ty and test­ing is­sues dur­ing a re­cent FDA in­spec­tion. The FDA in­spect­ed

John­son & John­son’s oral IL-23 that it li­censed from Pro­tag­o­nist Ther­a­peu­tics ap­pears to be a weak­er pso­ri­a­sis treat­ment than some of its in­jectable com­pe­ti­tion, ac­cord­ing

HH&L Ac­qui­si­tion Co., a SPAC that went through a $360 mil­lion IPO in ear­ly 2021, has re­neged on its busi­ness com­bi­na­tion agree­ment. The Hong Kong-based

In­novent and IA­SO Bio re­ceived the first ap­proval in Chi­na for a CAR-T ther­a­py for mul­ti­ple myelo­ma. The ther­a­py, known as eque­cab­ta­gene au­toleu­cel, will be

NorthX Bi­o­log­ics, a cell and gene ther­a­py man­u­fac­tur­ing and de­vel­op­ment out­fit based in Mat­fors, Swe­den, has ac­quired a fa­cil­i­ty from Val­ne­va. As part of the

No­va­cyt made a cash of­fer for mol­e­c­u­lar di­ag­nos­tics and screen­ing so­lu­tions com­pa­ny Your­gene Health as it ad­justs from a ma­jor drop in rev­enue due to

As­traZeneca and Dai­ichi Sankyo’s multi­bil­lion-dol­lar an­ti­body-drug con­ju­gate al­liance has gen­er­at­ed a Phase III win, the part­ners say, beef­ing up the case that they have a

San­doz, Boehringer In­gel­heim, Sam­sung and oth­ers are now tak­ing their shot at Ab­b­Vie’s megablock­buster Hu­mi­ra, with launch­es of their biosim­i­lars on Sat­ur­day, and myr­i­ad ap­proach­es

Ca­me­na Bio­science, a UK biotech, raised $10 mil­lion as it works on im­prov­ing the ac­cu­ra­cy of DNA syn­the­sis. The Se­ries A, led by UK ven­ture

Promising data on new B-cell maturation antigen (BCMA)-directed bispecific antibodies were presented at the American Society of Clinical Oncology (ASCO) annual meeting. These included results